At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KLRA Kailera Therapeutics
Pre-Mkt 09-02 06:49:55 EDT
16.41
+1.01
+6.56%
盘前17.06
+0.65+3.96%
06:40 EDT
High17.06Low15.15Vol1.21M
Open15.21D1 Closing15.40Amplitude12.40%
Mkt Cap2.13BTradable Cap737.17MTotal Shares129.54M
T/O19.99MT/O Rate2.69%Tradable Shares44.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  08-13
Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-13
Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Benzinga Earnings  ·  08-13
Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million
Reuters  ·  08-13
Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million
Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027
THOMSON REUTERS  ·  08-13
Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027
Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027
THOMSON REUTERS  ·  08-13
Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
THOMSON REUTERS  ·  08-13
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kailera Therapeutics Names Nur Nicholson Chief Technology Officer
Reuters  ·  08-11
Kailera Therapeutics Names Nur Nicholson Chief Technology Officer
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
THOMSON REUTERS  ·  08-11
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Kailera Therapeutics Inc Expected to Post a Loss of 75 Cents a Share - Earnings Preview
Reuters  ·  08-11
Kailera Therapeutics Inc Expected to Post a Loss of 75 Cents a Share - Earnings Preview
Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Earnings Agent  ·  08-05
Earning Preview: Kailera Therapeutics this quarter’s revenue is expected to increase by 0%, and institutional views are bullish
Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning
Reuters  ·  07-09
Kailera Therapeutics Files Form 3 for Chief Corporate Affairs Officer Kathleen Tregoning
Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  07-08
Jefferies Keeps Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  07-08
Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC) and Kailera Therapeutics, Inc. (KLRA)
Race to Launch Weight-loss Pills Heats up as Smaller Players Advance
Reuters  ·  07-08
Race to Launch Weight-loss Pills Heats up as Smaller Players Advance
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  07-07
Wall Street Analysts Are Bullish on Top Healthcare Picks
Kailera Therapeutics announces positive Phase 3 data for weight loss drug
TIPRANKS  ·  07-07
Kailera Therapeutics announces positive Phase 3 data for weight loss drug
Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China
THOMSON REUTERS  ·  07-07
Shares of Kailera Therapeutics up 1.9% Premarket After Weight-loss Drug Meets Main Goal of Late-stage Trials in China
Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success
Reuters  ·  07-07
Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success
Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials
Reuters  ·  07-07
Kailera's GLP-1 Drug Meets Main Goal of Late-stage Trials

Introduction

Company Name.
Kailera Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Kailera Therapeutics, Inc. was incorporated under the laws of Delaware on May 8, 2024. The company is a clinical-stage biotechnology company dedicated to ushering in a new era of obesity treatment through the advancement of a diversified R&D pipeline. It is currently rapidly advancing four clinical-stage product candidates that leverage multiple glucagon-like peptide-1 (GLP-1)-based mechanisms of action and routes of administration.
Issue price:
--